In a 68-year-old woman with BMI 40, urine creatinine 46.2 mg/dL, urine albumin <0.12 mg/dL, cystatin C 1.2 mg/L (eGFR 55 mL/min/1.73 m²) and serum creatinine 0.93 mg/dL (eGFR 67 mL/min/1.73 m²), what is the appropriate diagnosis and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Diagnosis: Stage 3a CKD with Discordant GFR Estimates

This patient has Stage 3a chronic kidney disease (CKD) that requires confirmation with cystatin C-based eGFR, given the significant discordance between creatinine-based eGFR (67 mL/min/1.73 m²) and cystatin C-based eGFR (55 mL/min/1.73 m²) in the context of class III obesity (BMI 40). The absence of albuminuria (<0.12 mg/dL, which translates to a urine albumin-to-creatinine ratio well below 30 mg/g) indicates CKD without significant proteinuria 1, 2.

Understanding the Discordance

The 12 mL/min/1.73 m² difference between the two eGFR values is clinically significant and directly related to this patient's obesity:

  • Creatinine-based eGFR overestimates kidney function in obesity: In patients with BMI ≥30 kg/m², serum creatinine-based equations systematically overestimate GFR because obesity is associated with relatively lower muscle mass per unit body weight, leading to lower creatinine production 3, 4.

  • Cystatin C-based eGFR may underestimate in obesity: Cystatin C levels can be elevated in obesity independent of GFR, potentially leading to underestimation of kidney function 4.

  • The combined equation (eGFRcr-cys) provides the most accurate assessment: The 2024 KDIGO guidelines specifically recommend using equations combining both creatinine and cystatin C for the most accurate GFR estimation, particularly in patients with extremes of body habitus 5, 6. Recent 2025 data confirms that indexed eGFRcr-cys outperforms either marker alone across the BMI spectrum, with 89% of estimates falling within 30% of measured GFR 3, 7.

Recommended Diagnostic Approach

Calculate eGFRcr-cys using the 2021 CKD-EPI equation that combines both creatinine and cystatin C 1, 5. This will provide the most accurate estimate of this patient's true kidney function and determine whether she has:

  • Stage 3a CKD (eGFR 45-59 mL/min/1.73 m²), or
  • Stage 3b CKD (eGFR 30-44 mL/min/1.73 m²)

The combined equation is expected to yield a value between the two discordant estimates, likely closer to the cystatin C-based value given the obesity 3.

Confirm CKD Diagnosis

Since the urine albumin is normal (<30 mg/g), CKD diagnosis requires persistent eGFR <60 mL/min/1.73 m² for at least 3 months 1, 8, 9. Repeat the combined creatinine-cystatin C measurement in 3 months to confirm chronicity 1, 2.

Management Strategy

Immediate Actions:

  1. Screen for CKD complications (indicated when eGFR <60 mL/min/1.73 m²) 2:

    • Blood pressure at every visit (target <130/80 mmHg if develops albuminuria, <140/90 mmHg without albuminuria) 8
    • Serum electrolytes (sodium, potassium, bicarbonate)
    • Hemoglobin and iron studies
    • Calcium, phosphate, parathyroid hormone, vitamin D
    • Fasting lipid panel

  2. Assess for diabetes: Given the obesity and CKD, screen with HbA1c or fasting glucose 1, 2. If diabetic, this significantly impacts management.

  3. Review medications: Adjust doses for eGFRcr-cys value, not creatinine-based eGFR alone 5. Avoid nephrotoxic agents (NSAIDs, certain antibiotics).

Ongoing Management:

If diabetic (which should be determined):

  • SGLT2 inhibitor with proven kidney benefit (e.g., dapagliflozin, empagliflozin) is recommended for patients with type 2 diabetes and eGFR ≥20 mL/min/1.73 m² 1
  • Metformin can be used if eGFR ≥30 mL/min/1.73 m²; reduce dose to 1000 mg daily if eGFR 30-44 mL/min/1.73 m² 1
  • Statin therapy (moderate to high intensity depending on cardiovascular risk) 1
  • Target HbA1c ~7% 2

If not diabetic:

  • Focus on blood pressure control
  • Statin if indicated for cardiovascular risk
  • Weight reduction counseling (critical given BMI 40)

Monitoring Frequency:

For Stage 3a CKD without albuminuria, monitor eGFR and urine albumin every 6-12 months 8. If Stage 3b, increase to every 3-6 months 8.

Critical Pitfalls to Avoid

  1. Do not rely on creatinine-based eGFR alone in this obese patient: This will lead to underestimation of CKD severity and inappropriate medication dosing 5, 3.

  2. Do not assume normal kidney function based on serum creatinine of 0.93 mg/dL: This is falsely reassuring in the context of obesity and reduced muscle mass 5, 6.

  3. Do not start ACE inhibitor or ARB without albuminuria or hypertension: These are only indicated when urine albumin ≥30 mg/g or blood pressure is elevated 1, 8.

  4. Monitor for acute kidney injury: This patient is at higher risk given CKD, obesity, and potential medication exposures 2.

References

4
Research

Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009

7
Research

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008

Related Questions

How should I manage a patient with serum creatinine 1.55 mg/dL (creatinine‑based eGFR ≈48 mL/min/1.73 m²), cystatin C 1.3 mg/L (cystatin C‑based eGFR ≈53 mL/min/1.73 m²), and BMI 37 (class II obesity)?
What is the appropriate management of elevated kidney function tests (e.g., increased serum creatinine or decreased estimated glomerular filtration rate) in a patient taking amiodarone?
In an elderly female patient with dementia, can renal function be estimated using only serum creatinine, or is creatinine clearance required?
What is the estimated glomerular filtration rate using the combined creatinine‑cystatin C (CKD‑EPI) equation for a 39‑year‑old male with serum creatinine 0.9 mg/dL, cystatin C 1.16 mg/L, and low muscle mass?
How do I calculate age-related estimated glomerular filtration rate (eGFR) using serum creatinine?
Can oral contraceptive pills exacerbate migraines, particularly in women with migraine with aura?
What does sickle cell trait indicate about the parents' carrier status?
What is the maximum recommended dose of zaleplon for adults, and how should it be adjusted for elderly patients or those with hepatic impairment?
What antipsychotic augmentation options can be used with clozapine when amisulpride, lithium, and aripiprazole (Abilify) are contraindicated?
Can the CT head without contrast findings (mild microangiopathic white‑matter changes, mild diffuse brain volume loss, and bilateral carotid‑siphon calcifications) explain the elderly patient’s generalized decline and fatigue?
In an elderly patient with bipolar mania, dyskinesia, and insomnia who is already taking divalproex sodium (Depakote) 500 mg twice daily, how should the psychotropic regimen be adjusted?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.